Kiwi Biosciences
S21
Active

Kiwi Biosciences

Patent-pending enzymes to break down common dietary triggers

Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food.

David Hachuel

Formerly co-founder and CEO at auggi.ai, a digital gut health coach for patients with Irritable Bowel Syndrome (IBS). auggi was recently acquired by Seed Health. Completed my MPH in Epidemiology at the Harvard School of Public Health and a Master's in Computer and Information Science at Cornell University.

David Hachuel
David Hachuel
Kiwi Biosciences

Anjie Liu

Interdisciplinary thinker: scientifically-minded; humanist at heart Joint concentration in physics and comparative literature (Harvard 2017), now submerging myself into the intricate world of biology. I've struggled with chronic gut issues for most of my adult life, which led me to developing the current formulation of FODZYME and launching Kiwi Biosciences.